AbstractBackgroundIn the United States (US), early Alzheimer’s disease (AD) is underdiagnosed due to numerous factors such as inadequate lab testing, lack of symptom awareness, misdiagnosis, and social stigma. AD has a long prodromal stage, and the potential for early diagnosis is important to effectively use disease‐modifying drugs. Our research aims to estimate the prevalence of mild cognitive impairment (MCI) and mild dementia due to AD among individuals ≥60 years old in the US.MethodUsing currently available data from a comprehensive literature review in a population cascade calculation, this study estimates the diagnosed prevalence of early AD in the US. It also evaluates uncertainty associated with different estimates using all upper or all lower 95% confidence intervals reported in the literature and highlights data gaps for estimating the population living with MCI and mild dementia due to AD.ResultWe estimated that in 2022 approximately 666,646 individuals (0.87% of those aged 60 years and older) had MCI due to AD (range: 351,926 – 1,227,776) and approximately 620,850 individuals (0.81% of those aged 60 years and older) had mild dementia due to AD (range: 445,082 – 820,339). In a US population of 76 million aged 60 or older in 2022, the size of the population with MCI due to AD and mild dementia due to AD increased with age, from 103,947 individuals in people 60‐64 years of age to 264,915 in people ≥90 years of age.ConclusionCurrent data sources suggest that the range of prevalence of MCI due to AD or mild dementia due to AD in the US is wide, but estimates are similar to other studies in literature. Slight differences may reflect changes in diagnostic tools, alternative prevalence sources used in computation, and alternative (PET, CSF) cutoffs to determine amyloid positivity. As new amyloid‐targeting therapies become available, additional research to obtain accurate estimates on diagnosis and amyloid positivity in more real‐world populations are required to reduce uncertainty. Given challenges around diagnosis and access to technology and specialists, planning will be required to optimize the value of new treatment advances such as amyloid‐targeting therapies.
Read full abstract